FDA Misses PDUFA Date for Savara's Lead Rare-Lung Drug, No New Timeline Given
SVRA sits 27% above its 52-week low of $4.13 on elevated volume (4.8× avg).
Summary
The FDA told Savara it will not act on the molgramostim BLA for autoimmune PAP by the November 22, 2026 PDUFA date, and the agency has not given a new action date. The review is still ongoing, so this is a delay rather than a rejection — but it removes the near-term approval event the stock has been trading on. Savara is pre-revenue and burning cash: it posted a $43.0 million Q3 loss and ended September with $129.6 million in cash and investments, so every month of delay pushes the commercial launch and any revenue further out while spending continues. The company has no approved products and molgramostim is its lead and only late-stage asset, so the entire thesis now hinges on an unscheduled FDA decision.
Updates
· Benzinga — Savara shares fell 18% to $4.27 after the FDA said it would not act on the molgramostim BLA by the November 22, 2026 PDUFA date.
At the time of this announcement, SVRA was trading at $5.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.13 to $7.01. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: BusinessWire.